Little Green Pharma’s Danish subsidiary will supply a high-THC strain of medicinal cannabis to Germany under a new deal with Cologne-based importer Cannamedical Pharma.

It is the fourth agreement struck by LGP to export medicinal cannabis to Europe’s largest cannabis market following previous deals with Four20 Pharma, Illios Sante and Demecan.

Under the agreement, LGP will supply the high-THC product into Germany on an exclusive basis should Cannamedical order specified minimum quantities every six months.

LGP said final development of the strain is expected within two to six months, with the first shipment due in the first half of 2023.

LGP claimed the deal has a potential value of more than A$4.5 million (€3 million) over two years.

“The agreement represents continued validation of LGP’s key strategy of developing bespoke, high-value white label strains for export to lucrative jurisdictions,” it said in a statement.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...

Leave a comment